Breaking News, Collaborations & Alliances

Piramal Partners with IntoCell to Explore Opportunities in ADC Development

Agreement expands Piramal’s payload-linker platform and bioconjugate abilities.

Author Image

By: Charlie Sternberg

Associate Editor

Piramal Pharma Solutions, a global Contract Development and Manufacturing Organization (CDMO), has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc., a Korean biotechnology company specializing in innovative antibody-drug conjugate (ADC) linker and payload platform technologies. Pursuant to this non-exclusive and non-binding agreement, IntoCell will explore licensing opportun...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters